Source: ERJ Open Res, 3 (3) 00004-2017; 10.1183/23120541.00004-2017
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Guy Brusselle, Janice Canvin, Sivan Weiss, Shawn X. Sun, Roland Buhl. Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy. ERJ Open Res, 3 (3) 00004-2017; 10.1183/23120541.00004-2017

Member's Comments

No comment yet.

Related content which might interest you: Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3, placebo (PBO)-controlled trials Source: International Congress 2016 – Asthma management Year: 2016 Efficacy of omalizumab in patients with moderate-to-severe allergic asthma that is poorly controlled on GINA (1998) treatment step 3 or 4 Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 SQ HDM SLIT-tablet is effective in patients not well-controlled in GINA treatment steps 2-4 Source: International Congress 2016 – Asthma management Year: 2016 10 Year evaluation of patients with severe uncontrolled allergic asthma treated with Omalizumab. Source: International Congress 2018 – Physiological and biological insights in asthma Year: 2018 Characteristics of the uncontrolled asthmatic patients on GINA step 4 treatment in Korea Source: Annual Congress 2012 - Epidemiology of asthma Year: 2012 Asthma exacerbations and eosinophilic inflammation 6 months after treatment with mepolizumab in refractory eosinophilic asthma Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 BTS Difficult Asthma Registry: Effect of omalizumab dosing table expansion on size of population of severe persistent allergic asthma patients potentially eligible for omalizumab therapy Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma Year: 2012 Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016 Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma Source: ERJ Open Res, 7 (4) 00465-2021; 10.1183/23120541.00465-2021 Year: 2021 Clinical experience with montelukast plus ICS vs. only ICS in non-asthmatic eosinophilic bronchitis (NAEB) in Indian patients Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016 Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with medium-dose ICS/LABA therapy (on GINA step 4) prior to study entry: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Adherence to the treatment of patients with bronchial asthma Source: International Congress 2015 – Is asthma always an easy disease to diagnose and manage? Year: 2015 Follow-up of patients with moderate-severe allergic asthma treated with omalizumab Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010 Safety of bronchial thermoplasty out to 5 years in patients with severe refractory asthma: Research in severe asthma (RISA) trial Source: Annual Congress 2011 - New treatments for airway disease Year: 2011 Adherence and effectiveness of omalizumab treatment in severe allergic asthma patients: Do the patients like injectable treatment? Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Characteristics of asthma patients responding to anti-IgE therapy Source: Annual Congress 2013 –Diagnosis and management of respiratory diseases Year: 2013 Overall asthma control with budesonide/formoterol maintenance and reliever therapy in patients stratified by GINA treatment step Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 Long-term (5 year) safety of bronchial thermoplasty in patients with moderate to severe asthma: Asthma Intervention Research (AIR) Trial Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 Study of the Glutoxim-containing inhalation treatment in bronchial asthma patients Source: Eur Respir J 2002; 20: Suppl. 38, 373s Year: 2002